Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia

Haemophilia

Volumn 15, Issue 3, 2009, Pages 676-685

  Martinowitz, Uri ^a   Luboshitz, J ^a   Bashari, D ^a   Ravid, B ^a   Gorina, E ^b   Regan, L ^b   Stass, H ^c   Lubetsky, A ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b BAYER CORPORATION   (United States)

^c BAYER PHARMA AG   (Germany)

Author keywords

Continuous FVIII infusion; Haemostasis; Recombinant FVIII; Surgery

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; SUCROSE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHOLECYSTECTOMY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG STABILITY; HEMOPHILIA A; HEMOSTASIS; HUMAN; JOINT PROSTHESIS; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SIDE EFFECT; SYNOVECTOMY; THROMBOPHLEBITIS; TOOTH EXTRACTION;

ADULT; BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; HEMOPHILIA A; HEMOSTASIS; HEMOSTATICS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; SUCROSE; TREATMENT OUTCOME;

EID: 65449189117     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01978.x     Document Type: Article

References (26)

1. Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol 2000; 110: 715-20.
2. Scharrer I, Brackmann HH, Sultan Y et al. Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia 2000; 6: 614-8.
3. Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992; 82: 729-34.
4. Batorova A, Martinowitz U. Continuous infusion of coagulation factors: current opinion. Curr Opin Hematol 2006; 13: 308-15.
5. Stachnik JM, Gabay MP. Continuous infusion of coagulation factor products. Ann Pharmacother 2002; 36: 882-91.
6. Martinowitz U. Stability of factor VIII preparation in continuous infusion. Ann Hematol 1994; 68(Suppl. 3): S69-71.
7. Schulman S, Gitel S, Martinowitz U. Stability of factor VIII concentrates after reconstitution. Am J Hematol 1994; 45: 217-23.
8. Hardisty RM, MacPherson JC. A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diath Haemorrh 1962; 7: 215-28.
9. Seghatchian MJ, Miller-Andersson M. A colorimetric evaluation of factor VIII: C potency. Med Lab Sci 1978; 35: 347-54.
10. Kirschbaum N, Wood L, Lachenbruch P et al. Calibration of the Ph. Eur. BRP Batch 3/Mega 2 (US/FDA) standard for human coagulation factor VIII concentrate for use in the potency assay. Pharmeuropa Spec Issue Biol 2002; 2002: 31-64.
11. Lee M, Morfini M, Schulman S, Ingerslev J, and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. The design and analysis of pharmacokinetic studies of coagulation factors. International Society for Thrombosis and Haemostasis. Available at: http://www.med.unc.edu/ isth/ssc/communications/factor8and9/fviiipharmaco.htm (last accessed on March 21 2001).
12. Abshire TC, Brackmann HH, Scharrer I et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy-International Kogenate-FS Study Group. Thromb Haemost 2000; 83: 811-6.
13. Martinowitz U, Schulman S, Horoszowski H, Heim M. Role of fibrin sealants in surgical procedures on patients with hemostatic disorders. Clin Orthop Relat Res 1996; 328: 65-75.
14. Batorova A, Martinowitz U. Continuous infusion of coagulation factors. Haemophilia 2002; 8: 170-7.
15. Hurst D, Zabor S, Malianni D, Miller D. Evaluation of recombinant factor VIII (Kogenate) stability for continuous infusion using a minipump infusion device. Haemophilia 1998; 4: 785-9.
16. Schulman S, Martinowitz U. Design and assessment of clinical trials on continuous infusion. Blood Coagul Fibrinolysis 1996; 7(Suppl. 1): S7-9.
17. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
18. Bjorkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: Methodology, pitfalls and applications. Haemophilia 1997; 3: 1-8.
19. De Bels D, Demeere JL, Dugauquier J, Louis P, Van der Vorst E. Continuous infusion of factor VIIIc during heart surgery in a patient with haemophilia A. Eur J Anaesthesiol 2004; 21: 984-6.
20. White B, Cotter M, Byrne M, O'Shea E, Smith OP. High responding factor VIII inhibitors in mild haemophilia - is there a link with recent changes in clinical practice? Haemophilia 2000; 6: 113-5.
21. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
22. Bidlingmaier C, Deml MM, Kurnik K. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections. Haemophilia 2006; 12: 212-7.
23. von Auer C, Oldenburg J, von Depka M et al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 2005; 1051: 498-505.
24. Gouw SC, Van Der Bom JG, Auerswald G, Ettinghausen CE, Tedgard U, Van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: The CANAL cohort study. Blood 2007; 109: 4693-7.
25. Peerlinck K, Arnout J, Di Giambattista M et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
26. Rosendaal FR, Nieuwenhuis HK, Van den Berg HM et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood 1993; 81: 2180-6.